ARD: A phase II randomized trial of the type I interferon inhibitor anivolumab in patients with active lupus nephritis

Objective: The type I interferon signaling pathway plays a role in the pathogenesis of lupus nephritis
.
Anifrugumab targets the type I interferon signaling pathway and is generally well tolerated in patients with systemic lupus erythematosus (SLE) , with efficacy across a range of clinically meaningful endpoints

.

Objective: The type I interferon signaling pathway plays a role in the pathogenesis of lupus nephritis

Methods: This phase II , double-blind study randomly assigned 147 patients ( 1:1:1 ) to receive monthly intravenous anifrugumab basic ( BR , 300 mg ), intensive ( IR , 900 mg × 3 , thereafter 300 mg ) or placebo, concomitantly with standard therapy (oral corticosteroids, mycophenolate mofetil) .

RESULTS: Patients received anifrugumab BR (n=45) , IR (n=51) or placebo (n=49)

Conclusions: Although the primary endpoint was not met, in patients with active lupus nephritis, anifrugumab IR improved endpoint values ​​including complete renal response at 52 weeks compared with placebo .

Source:

Jayne D, Rovin B, Mysler EF , et al .
Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis.
Annals of the Rheumatic Diseases2022; 81: 496-506.

Jayne D, Rovin B, Mysler EF , et al .

Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis.
Annals of the Rheumatic Diseases2022; 81: 496-506.
, et al Annals of the Rheumatic Diseases  81: Leave a message here